"It's not any different than hypertension or diabetes or the many other chronic illnesses that we deal with, where you have to use chronic medication." For over the past three years, the arrival of a new class of drugs known as GLP-1 agonists, so-called for their ability to mimic the action of the natural GLP-1 gut hormone that promotes satiety, has transformed the weight-loss field
Most national telehealth platforms, including PlexusDx, use an asynchronous health questionnaire reviewed by a PA-licensed clinician
By mimicking the GLP-1 hormone, it reduces hunger cravings and makes you feel fuller for longer after meals
While no significant dangers have been identified, ongoing supervision is recommended to monitor for any potential side effects
This week, the company released six-month randomized, sham-controlled data suggesting its endoscopic therapy, Revita, may blunt that rebound after GLP-1 discontinuation by intervening directly in the duodenum, where nutrient signals help determine the brains defended weight and metabolic set point
These medications regulate blood sugar, promote fullness, and support weight loss by mimicking hormones that stimulate insulin release